CGx Panel
FDA-Cleared Monkeypox Molecular Testing Laboratory
The Diagnostic Results Needed for Fast and Effective Healthcare Solutions
​
Diagnostic testing for the orthopoxvirus, including the Monkeypox viral infection, empowers clinicians with results. LUX Diagnostics offers DNA assay testing developed by the CDC and cleared by the FDA to effectively identify the disease by searching for the virus DNA.
​
We provide trusted data from our state-of-the-art laboratory to allow medical providers to make informed decisions and treatment plans. Our testing capacity, innovative equipment, software integration, and speed gives healthcare providers and patients reliable results.
CGx Result Categories
The results from the sample will report as detected, not detected, equivocal or inconclusive.
Detected
The test indicated the presence of a non-variola orthopoxvirus.
​
​
​
Not Detected
The test did not detect the orthopoxvirus, which indicates a negative result for Monkeypox.
​
​
Equivocal
The sample does not produce a definitive result because the level of the virus is too close to the detection limit. The CDC recommends collecting a new sample to test.
The CGx Testing Process
Simple and proven testing to improve healthcare outcomes through effective diagnostics.
​
-
The healthcare provider collects a sample by swabbing or brushing one of the patient’s lesions using a sterile swab.
-
Insert the swab into the approved tube and securely close the sample. Accurately label the sample for transport to the laboratory.
-
The healthcare provider sends the secure sample to LUX Diagnostics.
-
LUX Diagnostics processes the sample using innovative PCR testing technology.
-
The healthcare provider can access the patient’s results via the LUX LIMS portal.